Chinese Journal of Antituberculosis ›› 2018, Vol. 40 ›› Issue (9): 969-972.doi: 10.3969/j.issn.1000-6621.2018.09.012
• Original Articles • Previous Articles Next Articles
Jun ZHOU,Xiao-hui LYU,Xiu-qi ZHENG,Chao-gang XIONG,Yuan ZHAO,Li-yun DANG()
Received:
2018-03-08
Online:
2018-09-10
Published:
2018-10-17
Contact:
Li-yun DANG
E-mail:dangliyun@sina.com
Jun ZHOU,Xiao-hui LYU,Xiu-qi ZHENG,Chao-gang XIONG,Yuan ZHAO,Li-yun DANG. Comparative analysis of the adjustment success ratio of plasma drug concentration of three anti-tubercular drugs[J]. Chinese Journal of Antituberculosis, 2018, 40(9): 969-972. doi: 10.3969/j.issn.1000-6621.2018.09.012
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2018.09.012
[1] |
Motta I, Calcagno A, Bonora S . Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? Expert Opin Drug Metab Toxicol, 2018,14(1):59-82.
doi: 10.1080/17425255.2018.1416093 URL |
[2] |
Dheda K, Gumbo T, Gandhi NR , et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med, 2014,2(4):321-338.
doi: 10.1016/S2213-2600(14)70031-1 URL pmid: 24717628 |
[3] |
Jing Y, Zhu LQ, Yang JW , et al. Population pharmacokinetics of rifampicin in Chinese patients with pulmonary tuberculosis. J Clin Pharmacol, 2016,56(5):622-627.
doi: 10.1002/jcph.643 URL pmid: 26387492 |
[4] |
Jain A, Dixit P . Multidrug-resistant to extensively drug resis-tant tuberculosis: what is next? J Biosci, 2008,33(4):605-616.
doi: 10.1007/s12038-008-0078-8 URL pmid: 19208985 |
[5] | Chen G, Wu SQ, Feng M , et al. Association of UGT2B7 poly-morphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han. Int J Immunopathol Pharmacol, 2017,30(4):434-438. |
[6] |
Chogtu B, Surendra VU, Magazine R , et al. Rifampicin-Induced Concomitant Renal Injury and Hepatitis. J Clin Diagn Res, 2016,10(9):18-19.
doi: 10.7860/JCDR/2016/21030.8578 URL pmid: 27790502 |
[7] | Lv XZ, Tang SW, Xia YY , et al. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study. PloS One, 2013,8(6):e6503. |
[8] |
魏香兰, 方如塘, 师延峰 , 等. 抗结核药物的血药浓度监测结果分析. 中国医院药学杂志, 2015,35(21):1918-1921.
doi: 10.13286/j.cnki.chinhosppharmacyj.2015.21.08 URL |
[9] | 赵嫄, 雷倩, 党丽云 , 等. 抗结核药物血药浓度监测工作的思考和展望. 中国防痨杂志, 2017,39(11):1228-1232. |
[10] | World Health Organization. Global tuberculosis report 2016. Geneva: World Health Organization, 2016. |
[11] |
Choi R, Jeong BH, Koh WJ , et al. Recommendations for optimizing tuberculosis treatment: therapeutic drug monitoring, pharmacogenetics, and nutritional status considerations. Ann Lab Med, 2017,37(2):97-107.
doi: 10.3343/alm.2017.37.2.97 URL |
[12] | 吴雪琼, 张宗德, 乐军 . 分枝杆菌分子生物学. 北京: 人民军医出版社, 2010: 124-125. |
[13] |
周俊, 吕小会, 刘元 , 等. 三种抗结核药物血药浓度在个体及药物间的差异研究. 中国防痨杂志, 2017,39(5):482-487.
doi: 10.3969/j.issn.1000-6621.2017.05.014 URL |
[14] |
Wang PC, Pradhan K, Zhong XB , et al. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B, 2016,6(5):384-392.
doi: 10.1016/j.apsb.2016.07.014 URL |
[15] |
Hemanth Kumar AK, Ramesh K, Kannan T , et al. N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis. Indian J Med Res, 2017,145(1):118-123.
doi: 10.4103/ijmr.IJMR_2013_15 URL |
[16] |
Nagel S, Streicher EM, Klopper M , et al. Isoniazid Resistance and Dosage as Treatment for Patients with Tuberculosis. Curr Drug Metab, 2017,18(11):1030-1039.
doi: 10.2174/1389200218666171031121905 URL pmid: 29086682 |
[17] |
Mukonzo JK, Nanzigu S, Waako P , et al. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure. Pharmacoge-nomics, 2014,15(11):1423-1435.
doi: 10.2217/pgs.14.73 URL |
[18] |
Devaleenal DB, Ramachandran G, Swaminathan S . The challenges of pharmacokinetic variability of first-line anti-TB drugs. Expert Rev Clin Pharmacol, 2017,10(1):47-58.
doi: 10.1080/17512433.2017.1246179 URL pmid: 27724114 |
[19] |
Srinivas NR . Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms. Drugs R D, 2016,16(2):141-148.
doi: 10.1007/s40268-016-0133-0 URL |
[1] | LIU Xiao-li, LEI Li-mei, GUO Zhou-li, HUANG Yin, XU Jing, ZHAO Xia, WANG Yan, FU Li. Study on the relationship of stigma and social support of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 1002-1008. |
[2] | Academic Working Committee of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of fixed-dose combination formulations [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 885-893. |
[3] | JIN Hong-jian. The construction of tuberculosis prevention and control service system at county level in China needs to be strengthened urgently —— Comments and suggestions of an old tuberculosis control and prevention worker [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 896-902. |
[4] | ZHANG Can-you, XIA Hui, CHENG Jun. Testing and reporting requirements for Class Ⅱ biosafety cabinet in tuberculosis laboratory [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 903-909. |
[5] | ZHOU Lin, LIU Er-yong, MENG Qing-lin, CHEN Ming-ting, ZHOU Xin-hua, GAO Wei-wei, LIN Ming-gui, XIE Ru-ming. Evaluation of the quality of pulmonary tuberculosis diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standards [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 910-915. |
[6] | LIU Er-yong, WANG Qian, ZHOU Lin, ZHANG Guo-qin, ZHANG Xiu-lei, MA Yong-cheng, YANG Shu-min, WANG Cui, MENG Qing-lin, CHEN Ming-ting, LIN Ming-gui, TU De-hua.. Analysis of diagnostic quality of pulmonary tuberculosis with negative etiology in some areas of China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 916-920. |
[7] | MENG Qing-lin, LI Jin-lan, LIN Ding-wen, MA Yong-cheng, HOU Shuang-yi, LIU Nian-qiang, ZHOU Lin. Analysis of the awareness about knowledge on the updated TB diagnosis standard among the practitioners in TB control institutions [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 921-925. |
[8] | WANG Qian, ZHOU Lin, LIU Er-yong, ZHAO Yan-lin, LI Tao, CHEN Ming-ting, YANG Li-jia, WANG Jia.. A survey on the diagnostic ability of tuberculosis in the county-level medical institutions in China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 926-930. |
[9] | LI Ting, HE Jin-ge, SU Qian, LI Jing, LI Yun-kui, GAO Wen-feng, GAO Yuan, YANG Wen. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 931-936. |
[10] | LI Yun-kui, HE Jin-ge, SU Qian, LI Ting, LI Jing, GAO Wen-feng, YANG Wen, MAO Guang-yu. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 937-941. |
[11] | SU Qian, XIA Yong, LU Jia, WANG Dan-xia, HE Jin-ge. Analysis on the epidemiological characteristics of pulmonary tuberculosis among children aged 0-14 in Sichuan Province from 2009 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 942-947. |
[12] | DENG Ya-li, ZHANG Tian-hua, LIU Wei-ping, ZHANG Hong-wei, MA Yu, LI Peng.. Temporal and spatial clustering analysis of pulmonary tuberculosis incidence in Shaanxi Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 948-955. |
[13] | DONG Xiao, ZHAO Zhen, LIU Nian-qiang, WANG Sen-lu, CUI Yan. Analysis of the finding characteristics of pulmonary tuberculosis in the elderly population in Xinjiang Uygur Autonomous Region during 2009—2017 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 956-961. |
[14] | MA Ting-long, HAN Yi, CHENG Xu, LIU Zhi-dong. Clinical observation on treatment effectiveness of transdermal ultrasound-mediated drug delivery combined with oral anti-tuberculosis drug in patients with chest wall tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 968-972. |
[15] | NAN Hai, ZHANG Yun, YANG Xin-ting, DUAN Hong-fei. Meta-analysis on the diagnostic value of GeneXpert MTB/RIF for bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 973-980. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||